When the regulator and the investor are the same person.

To understand why committee assignments matter so much in the context of stock trading, you need to understand what being on a congressional committee actually gives you. It's not just a title. It's a structural information advantage that operates continuously, across every session of Congress.

Committee members receive classified briefings on topics within their jurisdiction. They hear from industry executives, regulators, and agency heads in closed-door sessions before any of that testimony is public. They participate in markup sessions where the actual text of legislation is drafted and amended, often weeks or months before a bill reaches the floor. They field calls from lobbyists representing the companies whose fate they're about to determine. And they vote, directly and often with advance notice of the outcome, on appropriations, regulations, and contract authorizations that move stock prices.

None of this is secret. It's how Congress is supposed to work. The problem is that it creates conditions under which a senator on the Armed Services Committee, for example, would have a meaningful edge over any other investor when deciding whether to buy a defense contractor. They know things about the procurement pipeline, the budget trajectory, and the regulatory climate that the public does not. And as long as they're allowed to hold and trade individual stocks in those same sectors, the incentive to exploit that edge is always present.

This isn't a handful of bad actors. A 2022 New York Times investigation found that 97 members of Congress reported trades from 2019 to 2021 that overlapped with their committee assignments. That's nearly one in five elected representatives and senators. The same study found that 44 of the 50 most active congressional stock traders bought or sold securities in companies over which their committee work gave them a potential information advantage.

A February 2026 CNN analysis identified at least ten sitting senators whose disclosed trades directly overlapped with sectors their committees oversee. The list was bipartisan: Republicans Bill Hagerty, John Kennedy, Ashley Moody, Jerry Moran, Bernie Moreno, Markwayne Mullin, and Tommy Tuberville. Democrats John Hickenlooper, Gary Peters, and Sheldon Whitehouse. Not fringe members or known bad actors. Senior senators serving on some of the most powerful committees in Congress.

A separate study published through CEPR found that members in congressional leadership, who sit on more committees and have access to a wider range of confidential deliberations, outperform rank-and-file members by up to 47 percentage points per year on their stock trades. That gap does not appear by accident.

The STOCK Act made insider trading illegal for members of Congress using material non-public information obtained through their official duties. But proving insider trading requires demonstrating that a specific piece of non-public information was the actual basis for a specific trade. That's an extremely high legal bar. In practice, almost no congressional trades meet it.

A senator can attend a closed-door briefing about an upcoming defense contract, walk out, and buy defense stocks. As long as they can credibly claim the trade was made on general market views or by an independent advisor, it's nearly impossible to prosecute. The information advantage is real. The legal exposure is minimal.

This is why the debate has shifted from "is this illegal?" to "should this be allowed at all?" The structural argument against congressional stock trading doesn't depend on proving crime. It depends on recognizing that the committee system creates information advantages that no private investor has, and that allowing the people with those advantages to trade individual stocks in the sectors they regulate is incompatible with the public interest, regardless of whether any specific trade crosses a legal line.

That's the argument behind the various ban proposals that have circulated in recent years, including the ETHICS Act. None has passed yet. See our full breakdown of why the congressional stock trading ban keeps stalling.

Most tools that track congressional trades display the raw disclosure data: who bought what, how much, and when. A few add portfolio views and politician-level statistics. Almost none systematically cross-reference each trade against the filer's committee assignments and the current legislative calendar.

That cross-reference is where the signal lives. A $50,000 buy in a pharmaceutical stock means something very different coming from a member of the Senate Health Committee during a drug pricing markup than it does coming from a member of the Agriculture Committee with no pharmaceutical oversight. The raw data looks identical. The context makes one of those trades worth paying attention to and the other essentially noise.

When you see a list of the most active stock traders in Congress, the sheer volume of trades can make it look like there's a lot to follow. But volume without committee context is the wrong lens entirely. The most active trader in Congress by transaction count is not necessarily the most interesting one. The most interesting trades are the ones where committee access, legislative timing, and position size all align in a way that makes the information advantage hard to dismiss.

This is the core of what Kapitol.ai reviews before publishing a trade. Not just what was traded but who traded it, what they oversee, and what was on the legislative calendar at the time.